Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;9(8):4469-4472.
doi: 10.21037/tcr-20-2061.

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B

Jesus E Juarez  1 , Amar U Kishan  1
Affiliations
Editorial

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B

Jesus E Juarez et al. Transl Cancer Res. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-2061). AUK reports grants and personal fees from ViewRay, Inc., personal fees from Varian Medical Systems, Inc., Intelligent Automation, Inc., other from Janssen, Inc., outside the submitted work. JEJ has no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. 10.3322/caac.21551 - DOI - PubMed
    1. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. 2020. Accessed 4/15/2020. Available online: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
    1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101. 10.1016/S0360-3016(98)00438-6 - DOI - PubMed
    1. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60. 10.1016/S1470-2045(16)30102-4 - DOI - PMC - PubMed
    1. Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 2016;34:2325-32. 10.1200/JCO.2016.67.0448 - DOI - PMC - PubMed